Novel tyrosine kinase inhibitor sulfatinib for the treatment of neuroendocrine neoplasms

• At: Seville (Spain) (2022)
• Type: Digital
• By: CUI, Yingjie (Department Of Pharmacy, Shandong Provincial Hospital Affiliated To Shandong First Medical University, China)
• Co-author(s): Prof Ning Hou, Vice Director (Department Of Pharmacy, Shandong Provincial Hospital Affiliated To Shandong First Medical University, Jinan, China)
  Prof Yingjie Cui
  
• Abstract:

  Abstract：Sulfatinib, a novel oral tyrosine kinase inhibitor independently developed in China that selectively targets Vascular endothelial growth factor receptor, Fibroblast growth factor receptor 1 and Colony-stimulating factor 1 receptor kinases, possesses a dual mechanism of anti-angiogenesis and immunomodulatory, thereby generating the..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login